INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus.

Trial Profile

INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Mantle-cell lymphoma; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INHIBITOR
  • Sponsors Pfizer
  • Most Recent Events

    • 07 May 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 01 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
    • 01 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top